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Abstract
Background: The purpose of this study was to investigate the potential of cerebrospinal fluid miRNAs as diagnostic
biomarkers of acute ischemic stroke using three different profiling techniques in order to identify and bypass any
influence from technical variation.
Methods: Cerebrospinal fluid (CSF) from patients with acute ischemic stroke (n = 21) and controls (n = 21) was
collected by lumbar puncture. miRNA analysis was performed with three different methods: 1) Trizol RNA extraction
followed by Illumina Next Generation Sequencing (NGS) on all small RNAs, 2) Exiqon RNA extraction protocol and
miRNA qPCR assays, and 3) validation of 24 selected miRNAs with Norgen Biotek RNA extraction protocol and
Applied Biosystems qPCR assays.
Results: NGS detected 71 frequently expressed miRNAs in CSF of which brain-enriched miR-9-5p and miR-128-3p
were significantly higher in CSF of stroke patients compared to controls. When dividing stroke patients into groups
according to infarct size several brain-enriched miRNAs (miR-9-5p, miR-9-3p, miR-124-3p, and miR-128-3p) were
elevated in patients with infarcts >2 cm3. This trend appeared in data from both NGS, qPCR (Exiqon), and qPCR
(Applied Biosystems) but was only statistically significant in some of the measurement platforms.
Conclusions: Several brain-enriched miRNAs are elevated in the CSF three days after stroke onset, suggesting that
these miRNAs reflect the brain damage caused by ischemia. The expression differences seem, however, limited to
patients with larger ischemic brain injury, which argues against the use of CSF miRNAs as diagnostic biomarkers of
stroke based on current methods.
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Background
Ischemic stroke is a frequent cause of death and disability
all over the world. In patients with atypical or discrete
symptoms the diagnosis of ischemic stroke can be difficult
and determining the cause of stroke in each individual is
even more complicated. Despite thorough clinical and
paraclinical evaluation comprising brain computed tom-
ography (CT) or magnetic resonance imaging (MRI),
blood tests, cardiac workup, and ultrasound examination
of the carotid arteries, the cause of acute ischemic stroke
remains unknown in 25% of all patients [1]. A biomarker
with the ability to distinguish between different stroke
etiologies (large-artery atherosclerosis, small-artery oc-
clusion, and cardio-embolism) could potentially aid the
physicians in choosing the best secondary prevention
for their patients since treatment of the different stroke
subtypes is not the same. In patients with large-artery
atherosclerosis or small artery occlusion, anti-platelet
drugs are first choice treatment for reducing the risk of
stroke recurrence [2]. In contrast, in patients with cardio-
embolic stroke, anticoagulant therapy is the most effective
prevention [3, 4]. Surgical intervention with carotid end-
arterectomy is considered in large-artery atherosclerosis
as it reduces recurrent strokes in patients with a
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significant ipsilateral carotid artery stenosis [5]. The
current and most widely used system for categorization of
ischemic stroke subtypes, the TOAST classification, is
based on clinical and paraclinical test results and has only
moderate inter-rater reliability [6, 7]. Furthermore, many
stroke patients have competing possible causes, such as
concurrent atrial fibrillation and carotid artery stenosis,
making it impossible to establish a specific etiology.
Therefore, new diagnostic and prognostic biomarkers in
relation to ischemic stroke are warranted and could po-
tentially benefit stroke patients in various ways.
MicroRNAs (miRNAs) are small non-coding RNA
molecules involved in numerous physiological processes
in which they function as posttranscriptional inhibitors
of gene expression. Their presence in different body
fluids such as blood and CSF combined with their stabil-
ity during long term storage make them interesting as
biomarker candidates [8–10]. Recently, several clinical
stroke studies have suggested a diagnostic value of miRNAs
extracted from plasma/serum and circulating blood cells
[11–15], although the results points in various directions.
Since CSF is separated from the blood by the blood brain
barrier (BBB) and because of its proximity to the brain tis-
sue, it is obvious to assume that the CSF could contain
unique signatures of miRNA expression specific for various
central nervous system (CNS) pathologies, and therefore
serve as a more valid biomarker source compared to other
body fluids.
Within few minutes after stroke onset, various brain
functions begin to break down as a direct consequence
of ischemia including changes in gene expression [16, 17].
Microarray studies have identified several gene families,
e.g. immediate early genes, heat shock protein genes, and
genes related to apoptosis and inflammation that are
regulated by focal brain ischemia [18–20]. Several experi-
mental studies have shown changes in the expression of
miRNAs in rat brain tissue following middle cerebral artery
occlusion [21–26]. Based on this knowledge, we hypothe-
sized that the changes in miRNA expression in the brain of
acute ischemic stroke patients are reflected in the cerebro-
spinal fluid (CSF) surrounding the central nervous system.
Previously, we have explored the expression of miRNAs
in CSF of acute stroke patients in a pilot study [27]. We
found 21 frequently expressed miRNAs in the CSF of
which two miRNAs (miR-221-3p and let-7c-5p) appeared
to be up-regulated in stroke patients compared to con-
trols, although not statistically significant after correction
for multiple testing.
The purpose of this follow-up study was 1) to investi-
gate the potential of CSF miRNAs as biomarkers of
acute ischemic stroke using three different profiling
techniques in order to identify and bypass any influence
from technical variation and 2) to validate our previous
findings in a larger group of patients.
Methods
Patient material and sample collection
Patients admitted with acute ischemic stroke at the De-
partment of Neurology, Nordsjællands Hospital, Univer-
sity of Copenhagen, from June 2013 to December 2014
were asked to participate in accordance with the approval
from the Danish Research Ethics Committee (project ID:
H-I-2011-094).
As in our previous study, the stroke diagnoses were
based on patient history, thorough neurologic examination
and CT scan of the brain on admission. In addition, all pa-
tients were scanned on a 3 Tesla System Philips Achieva
MRI scanner on the third day after symptom onset. The
imaging protocol consisted of diffusion-weighted and
T2-weighted sequences. Infarct volumes were calculated
from MR diffusion-weighted images by multiplying the
summed areas of infarction with the distance between
each section [28]. After additional Doppler Ultrasound
of carotid arteries and cardiac telemetry for at least 48 h
during admission patients were categorized according to
stroke subtype using the TOAST classification [6]. Con-
trols were recruited from our outpatient neurology clinic
as they underwent planned lumbar punctures as part of
their investigation program for neurologic diseases others
than stroke. A total of 42 patients were included, n = 21
ischemic stroke patients, and n = 21 controls. Patient
characteristics are given in Table 1. A more detailed de-
scription of the different diagnoses and stroke parameters
in each individual patient is given in Additional file 1. The
Table 1 Patient characteristics
Characteristics Stroke (n = 21)
Mean (range) or n (%)
Control (n = 21)
Mean (range) or n (%)
Age (years) 66.6 (47–78) 66.0 (31–86)
Male sex 12 (57.1) 13 (61.9)
NIHSS 2.5 (0–10) -
Infarct (cm3) 6.7 (0.3–32.4) -
SAO 11 (52.4) -
LAA 5 (23.8) -
CE 2 (9.5) -
U 3 (14.3) -
Dementia - 7 (33.3)
MCI - 2 (9.5)
Multiple sclerosis - 1 (4.8)
ALS - 1 (4.8)
No CNS disease - 10 (47.6)
NIHSS National Institute of Health Stroke Scale, SAO stroke caused by small-artery
occlusion LAA, stroke caused by large-artery atherosclerosis, CE stroke caused by
cardioembolism, U stroke of undetermined etiology,MCImild cognitive impairment,
ALS amyotrophic lateral sclerosis, No CNS disease patients with no evidence
of disease in the central nervous system (benign headache, Bell’s palsy,
polyneuropathy, restless legs or lower back pain)
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composition of diagnoses and severity of stroke symptoms
were comparable to our previous study, Additional file 2.
Lumbar punctures were done by sterile technique on
the third day after stroke onset with the use of a 0.7 mm
spinal needle in accordance with local guidelines. At least
5 ml CSF were collected from each patient. For miRNA
detection 1 ml CSF from each patient was centrifuged at
2000 x g at 4 °C for 15 min immediately after collection
and the cell-free fractions were stored at −80.0 °C. Ana-
lyses of miRNAs were performed by three different
methods as described below. A detailed description of the
methodology is available online, Additional file 3.
Trizol RNA extraction followed by Illumina next
generation sequencing
RNA was isolated from 100 μl CSF using TriZol reagent
(Invitrogen) according to the manufacturer’s protocol.
Small RNA libraries were prepared using the TruSeq
small RNA library preparation kit (Illumina). The result-
ing cDNA was amplified by PCR and all small RNA se-
quences were purified on gels and sequenced on a
NextSeq500 (Illumina). The libraries from two stroke
patient samples were of low quality and were therefore
excluded from further analysis. Reads were trimmed for
adapters and reads shorter than 15 nucleotides in length
were discarded. Small RNAs were aligned to the human
genome (hg19) and miRbase (v20) using sRNAbench
[29]. miRNA counts were normalized in R Bioconductor
package edger [30] using Trimmed Mean of M-values
(TMM). Fold changes were based on the average count
in each patient group.
Exiqon RNA extraction protocol and miRNA qPCR assays
RNA extractions and sample preparations were done by
Exiqon Services, Denmark. Total RNA was extracted
from 200 μl CSF using spin column chromatography
(miRCURY™ RNA isolation kit for bio fluids). RNA was
reverse transcribed using the miRCURY LNA™ Univer-
sal RT miRNA kit (Exiqon). Each miRNA was assayed
once by qPCR on the miRNA Ready-to-Use PCR, Hu-
man panel I containing 372 specific miRNA primers.
Amplification was performed in a LightCycler® 480
Real-Time PCR System (Roche) in 384 well plates.
Using NormFinder [31] the best normalizer was identi-
fied as the average Ct value of the 9 miRNAs detected
in all samples (miR-15a-5p, miR-21-5p, miR-23a-3p,
miR-23b-3p, miR-99a-5p, miR-125b-5p, miR-145-5p,
miR-204-5p, and miR-320a) and relative expression levels
(RELs) were calculated by the formula REL = 2miR average −
miR/2Global mean average −Global mean based on the principle of
2-ΔΔCt [32]. Fold changes were based on the median value
of REL in each patient group (missing values excluded).
Norgen Biotek RNA extraction protocol and applied
biosystems qPCR assays
Total RNA was extracted from 200 μl CSF using spin
column chromatography (Total RNA Purification Kit,
Norgen Biotek). Reverse transcription was performed by
TaqMan microRNA Reverse Transcription Kit per-
formed on a 2720 Thermal Cycler (Applied Biosystems).
miRNA specific pre-amplification was accomplished using
TaqMan PreAmp master mix and TaqMan MicroRNA
Assays (Applied Biosystems). Pre-amplified samples and
TaqMan miRNA assays for 24 selected miRNAs were ap-
plied to a 48.48 Dynamic Array IFC chip and amplified on
a BioMark real-time microfluidic PCR system (Fluidigm).
Normfinder [31] identified two equally good normalizers:
miR-320a and the average Ct value of the 20 miRNAs de-
tected in all samples. Based on the assumption that most of
the 24 miRNAs in this validation experiment were differen-
tially expressed between our patient groups we wanted to
avoid a global mean normalization that could potentially
undermine any differences by comparing raw data to the
average of all miRNAs. Therefore, miR-320a was chosen as
normalizer and RELs were calculated using the formula
REL = 2miR average−miR/2miR−320a average−miR−320a based on
the principle of 2-ΔΔCt [32]. Fold changes were based on the
median value of REL in each patient group (missing values
excluded).
Statistics
Two-sided nonparametric Mann-Whitney tests were per-
formed for REL comparisons between groups (SPSS
software). In the NGS experiment differentially expressed
miRNAs were detected by an exact test based on condi-
tional maximum likelihood (CML) included in the R Bio-
conductor package edgeR [30]. P values from NGS and
qPCR were corrected for multiple testing with the
Benjamini-Hochberg (BH) procedure and p < 0.05 were
considered significant. In all group comparisons missing
expression values were treated as zero. The NGS heat
map was generated using Multiple Experiment Viewer
[33]. Selection of the best miRNA predictors was based on
logistic lasso regression [34] performed on the top 15
most deregulated miRNAs detected by NGS. AUC and
classification accuracy was estimated by leave-one-out
cross-validation based on the seven predictors selected by
the lasso. Differences in total numbers of miRNAs be-
tween groups as well as differences in age were analyzed
by two-sided parametric t tests. Fischer’s exact test was
used for analysis of sex differences.
Results
Overall detection by NGS and Exiqon qPCR (human panel I)
A total of 246 miRNAs were detected in the CSF by
NGS of which 71 miRNAs were expressed in more than
90% of the patient samples. Slightly fewer, 210 miRNAs,
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were detected by the qPCR screening (Exiqon, human
panel I) of which only 21 miRNAs were expressed in
more than 90% of the samples. With the exception of
miR-1246 all of the differentially expressed miRNAs
between stroke patients and controls were detected by
both NGS and qPCR (Additional file 4) although the
detection rate was generally lower in the qPCR
experiment.
Results from NGS
In the NGS experiment only two miRNAs (miR-1246 and
miR-128-3p) were significantly up-regulated in the stroke
group compared to controls after BH correction. The up-
regulation of miRNAs was most evident in patients with
large-artery atherosclerosis or cardioembolism whose
infarcts were larger (mean volume (range) = 16.5 cm3
(2.5–32.4)) compared to patients with small-artery oc-
clusion (mean volume (range) = 0.7 cm3 (0.3–1.6)) (Fig. 1).
When dividing patients into groups according to infarct
size 8 miRNAs (miR-9-5p, miR-99b-5p, miR-103a-3p,
miR-107, miR-128-3p, miR-181a-5p, miR-181b-5p, and
miR-1246) were significantly up-regulated in patients with
infarcts >2.5 cm3 (n = 7) compared to stroke patients with
smaller infarcts (n = 12).
Results from qPCR screening (Exiqon, human panel I)
Consistent with our previous findings [27] qPCR (human
panel I, Exiqon) detected only 21 frequently expressed
miRNAs in CSF of which none were differentially regu-
lated between stroke patients and controls after BH cor-
rection. The up-regulation of miR-221-3p and let-7c-5p
found in our previous pilot study could not be validated.
By considering the expression in subgroups with different
infarct sizes two miRNAs (miR-9-3p and miR-124-3p)
were significantly up-regulated in stroke patients with in-
farcts >2 cm3 (n = 8) compared to stroke patients with
smaller infarcts (n = 13).
Validation of selected miRNAs by qPCR (applied
biosystems)
Following the completion of NGS and the first qPCR ex-
periment we selected miRNAs that showed differential
expression between stroke patients and controls (and/or
between patients with small and large infarcts) for tech-
nical validation. The selection was based on significant
unadjusted p values (p < 0.05) and/or a large fold change
(0.3 > FC > 3) in at least one of the two experiments. A
total of 21 selected miRNAs were included in the valid-
ation study (normalizers excluded). Table 2 summarizes
results for the 21 selected miRNAs measured with NGS,
qPCR (Exiqon), and qPCR (Applied Biosystems), re-
spectively. Five miRNAs (miR-9-5p, miR-9-3p, miR-107,
miR-124-3p, and miR-128-3p) were consistently up-
regulated in the group of patients with infarcts >2 cm3,
although not statistically significant throughout all meas-
urement platforms. At least four of them (miR-9-5p,
miR-9-3p, miR-124-3p, and miR-128-3p) are known as
brain-enriched miRNAs with a high tissue specificity
index [35]. miRNA-1246 showed the highest up-
regulation by NGS (FC = 13.6; p = 0.01) but did not
appear to be up-regulated by qPCR (Applied Biosys-
tems) and was unfortunately not included in the hu-
man panel I (Exiqon). Fig. 2 illustrates the expression
levels of the four brain-enriched miRNAs in different
patient subgroups.
Fig. 1 Heatmap showing logFC expression of the top 15 most differentially expressed miRNAs between stroke patients and controls detected by
Next Generation Sequencing. Fold changes were calculated as the expression in each sample (normalized count) relative to the average expression in
the control group. A: stroke patients with infarcts <2 cm3; AL: stroke patients with infarcts >2 cm3; C: control patients
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Classification accuracy and ROC curve
Although the strongest miRNA changes were seen in pa-
tients with larger infarcts we attempted to analyze the
predictive power of one or more miRNAs to separate
stroke patients from controls. Logistic lasso regression
performed on the top 15 most differentially expressed
miRNAs detected by NGS identified a combination of 7
miRNAs that could discriminate stroke patients from
controls with a classification accuracy of 0.75. Fig. 3 shows
the receiver operating characteristic (ROC) curve esti-
mated by leave-one-out cross validation (AUC = 0.80).
Discussion
Based on the hypothesis that acute stroke causes tran-
scriptomic changes in the brain tissue which is reflected
in the molecular profile of miRNAs in the CSF, we aimed
to search for a miRNA expression profile that would
uniquely identify stroke patients from other neurological
patients. Such a marker could potentially be useful in situ-
ations where the diagnosis may be uncertain (e.g. transient
ischemic attacks) or when the underlying cause of ische-
mic stroke remains unknown.
Obtaining a blood sample for measurement of miRNA
biomarkers is less invasive than a lumbar puncture. How-
ever, many organs are likely to contribute to the extracel-
lular miRNA content in plasma. Blood cells, in particular,
have been shown to be major sources of plasma miRNAs.
Pritchard et al. [36] showed that 58% of plasma miRNAs,
reported in the literature to be candidate biomarkers for
various cancers, are highly expressed in blood cells. This
raises the concern that many miRNAs reported as circu-
lating biomarkers reflect a secondary effect of blood cells
rather than a disease-specific effect. Since CSF is separated
from the circulation by the BBB and because of the con-
tinuous interchange between CSF and interstitial fluid
[37], it seems more likely that the composition of miRNAs
in CSF reflects CNS pathology better than that of blood
plasma. We therefore chose to examine miRNA expres-
sion in cell-free CSF samples.
In this comprehensive investigation of miRNAs in the
CSF from 21 stroke patients and 21 controls, encom-
passing both NGS and two different qPCR protocols, we
identified relatively few frequently expressed miRNAs in
the CSF. In general, the expressional variations within
groups and small fold changes between groups resulted
in no statistically differences for most of the detected
miRNAs. However, it is noteworthy that brain-enriched
miR-9-5p, miR-9-3p, miR-124-3p, and miR-128-3p were
consistently up-regulated in the group of patients with
infarcts >2 cm3 throughout all experiments.
Studies investigating the abundance of miRNAs in dif-
ferent human organs have identified miR-9-3p, miR-9-5p,
miR-124-3p, and miR-128-3p as being enriched in vari-
ous brain regions (midbrain, cortex, cerebellum and
Fig. 2 Scatter plots of the expression levels of four brain-enriched
miRNAs (miR-9-3p, miR-9-5p, miR-124-3p, and miR-128-3p) detected
by Next Generation Sequencing (A) and Exiqon qPCR (B). Large: stroke
patients with infarcts >2 cm3 (n = 13); Small: stroke patients with
infarcts <2 cm3 (n = 8); Control: control patients with various
neurological diseases other than stroke (n = 21)
Fig. 3 Receiver operating characteristic (ROC) curve showing the
diagnostic value of the combination of 7 miRNAs selected by logistic
lasso regression to discriminate stroke patients from controls.
AUC = 0.80, classification accuracy = 0.75. miRNAs included in the
model: miR-9-3p, miR-92b-3p, miR-99a-5p, miR-128-3p, miR-181a-5p,
miR-203a-3p, and miR-1246
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hippocampus) as well as being brain-specific with a
high tissue specificity index [35, 38]. Cell studies sug-
gest that miR-124 and miR-128 are predominantly
expressed in neurons [39] and studies on embryonic
stem cells imply that miR-9 and miR-124 play key roles
in neural fate determination in mammalian brain devel-
opment [40].
It is unknown whether disease-associated miRNAs in
CSF are involved in the pathogenic mechanisms of is-
chemic cell death in the CNS or reflect a passive mo-
lecular response to cerebral damage. Stroke-associated
miRNAs in the CSF may originate from cytoplasmic pro-
tein complexes released during neuronal and glial cell lysis
caused by brain ischemia. In this study, the overall amount
of miRNA in the CSF seemed slightly higher in patients
with larger infarcts compared to other stroke patients, al-
though not statistically significant. The total number of
different miRNAs detected by both qPCR and NGS was
significantly higher in the group of patients with infarcts
>2 cm3 (p = 0.03), which might indicate a general leak of
miRNAs into the CSF following ischemic cell injury and
ensuing cell lysis (Fig. 4).
Another possible origin of any miRNA in the CSF is
active release of miRNAs enclosed in small membranous
vesicles (exosomes) which may play a role in intercellu-
lar communication [41, 42]. Only one study has focused
on exosome-derived miRNAs in stroke patients. Ji et al.
[12] extracted exosomes from serum of 65 stroke
patients and 66 non-stroke controls with matching age
and cardiovascular risk factors. They found a generally
higher concentration of exosomes and a significant in-
crease of exosome derived miR-9 (FC = 16) and miR-124
(FC = 4) in the stroke group compared to controls, sug-
gesting that exosomes from the brain can somehow cross
the BBB and enter the peripheral circulation. Accordingly,
Ogata et al. [43] have shown elevation of miR-9-3p in the
hippocampus as well as in exosomes in peripheral blood
of mice after administration of trimethyltin that selectively
damages CNS neurons, indicating that miR-9-3p is a po-
tential marker of brain damage.
If the elevation of specific miRNAs in the CSF of
stroke patients is caused by expressional changes in the
brain tissue, these changes could possibly both reflect
the molecular chaos in the ischemic brain tissue as well
as its counterregulatory mechanisms. To search for pos-
sible molecular functions we made a combined miRPath
[44] (version 3.0) analysis of the up-regulated miR-9-3p,
miR-9-5p, miR-107, miR-124-3p, and miR-128-3p (results
merged by genes union, FDR correction, P < 0.05) which
identified several KEGG pathways relevant to ischemic
stroke, including pathways involved in p53 signaling, cell
cycling, tumor necrosis factor (TNF) signaling, hypoxia
inducible factor 1 (HIF-1) signaling and neurotrophin
signaling.
In literature, the expression of miR-128 has been linked
to alterations in the expression of genes implicated in
Fig. 4 Total number of different miRNAs detected by qPCR (A) and NGS (B). The general amount of miRNA is expressed as the average of
raw Ct values (C), and NGS total counts (D). All variables are shown as mean values (with standard error bars) among controls, patients with
infarcts <2 cm3 (small), and patients with infarcts >2 cm3 (large)
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apoptosis (Bcl-2, Bax, p53, and Bak) as well as angio-
genesis (VEGF) [45]. Yang et al. [46] found miR-128b
significantly up-regulated in plasma from ischemic
stroke patients compared to healthy controls. In addition,
miR-124 has previously been associated with ischemic
stroke. Liu et al. [47] as well as Sun et al. [48] found an in-
crease of miR-124 in the ischemic penumbra after per-
manent middle cerebral artery occlusion in mice. In both
studies cell culture experiments indicated that miR-124 is
involved in apoptosis. Recently, Li et al. [13] reported up-
regulation of three miRNAs in serum of stroke patients
including miR-1246, which had the highest fold change
(FC = 13.6; p = 0.01) in our NGS experiment. In summary,
these results, although not fully comparable, support our
findings. Only one study besides ours has focused on
miRNAs in CSF of stroke patients. Peng et al. [49] ana-
lyzed the expression of let-7e and miR-338 in CSF from
ischemic stroke patients and found up-regulation of let-
7e in a group of patients included 1–7 days after symptom
onset (n = 11) but they did not include any brain-specific
miRNAs in their analysis.
Despite our consistent experimental setup, uniform
sample handling, and data processing we were not able
to validate the results from our previous pilot study [27].
This might be due to the small differences found in our
pilot study, or the fact that none of our pilot study p
values passed a BH correction for multiple testing. These
results highlight the importance of performing follow-up
studies, especially when patient numbers are small. Exi-
qon’s protocol resulted in many missing values and had
a lower detection rate for many miRNA sequences com-
pared to NGS, which might explain why any potential
differences in brain-enriched miRNAs were not detected
in our previous pilot study. In addition, poorly elucidated
factors like heterogeneity of genetic background, differ-
ences in BBB function, CSF turnover, and miRNA degrad-
ation might have influenced results differently in the two
studies.
Limitations of our study include the relatively small
study population and heterogeneous control group with
regard to diagnoses. The various diagnoses represented
in our control group may have influenced the fold changes
calculated between stroke patients and controls. Neverthe-
less, if a stroke biomarker should be useful in the clinic, it
should possess enough power to predict the diagnosis of
ischemic stroke even when tested against non-healthy in-
dividuals. Therefore, and because of ethical issues in rela-
tion to doing lumbar punctures on healthy individuals, we
decided to use neurological patients as controls.
We initially planned to include three equal groups of
stroke patients with small-artery occlusion, large-artery
atherosclerosis, and cardioembolism. However, we had
to exclude patients from lumbar puncture if they were
unable to give informed consent, received anticoagulant
treatment, or had large infarctions with emerging vaso-
genic edema which contraindicated a lumbar puncture.
Therefore, our study population mainly consisted of pa-
tients with lacunar infarctions and a smaller group of
patients with larger infarcts having either cardioembo-
lism or large-artery atherosclerosis, which prevented us
from comparing miRNA expression profiles in sub-
groups based on stroke etiologies alone.
An advantage of our study is that it takes into consid-
eration the technical uncertainties related to miRNA
profiling by using three different profiling techniques on
the same sample set. We observed quite significant dis-
crepancies between results from NGS, qPCR (Exiqon),
and qPCR (Applied Biosystems). The low quantities of
miRNAs in the CSF combined with multiple factors such
as RNA extraction quality, affinity of the primers, and
PCR efficiency could influence the results in unpredict-
able ways. In addition, unknown biological factors such
as BBB function and CSF clearance may have influenced
our results.
Although the strongest miRNA expressional changes
were seen in patients with larger infarcts, we attempted
to analyze the predictive power of combining one or
more miRNAs to separate stroke patients from controls
with logistic lasso regression based on data from NGS.
The best model combined 7 miRNAs but resulted in an
overall unsatisfactory classification accuracy of 0.75.
Conclusion
In conclusion, several brain-enriched miRNAs are ele-
vated in the CSF three days after stroke onset, suggesting
that these miRNAs reflect the brain damage caused by is-
chemia. The expressional differences seem, however, lim-
ited to patients with larger ischemic injury, which argues
against the use of CSF miRNAs as diagnostic biomarkers
of stroke based on current methods.
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